Compare Cassava Sciences Inc (FLNA) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Xpeng Inc - ADR — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Xpeng Inc - ADR trades at $14.37 (market cap $12.82B). The key difference: Xpeng Inc - ADR is far larger — about 241.2× Cassava Sciences Inc's market cap, and Xpeng Inc - ADR is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | XPEV | |
|---|---|---|
Market Cap | $53.14M | $12.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $28.07 |
52-Week Low | $1.09 | $12.09 |
Enterprise Value | -$33.43M | $14.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
XPeng (XPEV) trades at $13.36, up 3.17% today, with a bullish technical signal despite mixed earnings. Revenue grew to $76.72B in 2025, but net losses persist at -$1.14B. Analyst consensus is 64.7% buy, supported by strong Q2 2026 deliveries and new model launches. Cash flow improved in 2025, though operational cash flow was negative in 2024.
Outlook is cautiously optimistic with recovery in vehicle sales and global expansion driving potential upside. Key risks include intense EV competition, regulatory pressures, and sustained profitability challenges. The stock's valuation at P/S 1.21 offers growth appeal if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
